FEATURES OF PRO-INFLAMMATORY CYTOKINES (IL-6 AND TNF-α) IN CHILDREN WITH COVID-19
DOI:
https://doi.org/10.11603/24116-4944.2024.1.14755Keywords:
COVID-19, children, interleukin-6, tumor necrosis factor-alfaAbstract
The aim of the study – to evaluate IL-6 and TNF-a levels in children with COVID-19 and their dependence on the severity of the disease
Materials and Methods. 112 children with COVID-19, aged 1 month to 18 years, who were hospitalized at the Department of Infectious Diseases of Ternopil City Children's Hospital were examined. The level of IL-6 and TNF-a in serum samples was determined by enzyme-linked immunosorbent assay using standard kits (BT Lab, China).
Results and Discussion. The average age of children was (7.04±5.75) years (95% CI 5.96−8.12). Regarding disease severity, 57 children (42.23%) had a mild course of the disease, 43 children (31.86%) had a moderate course, and 12 children (8.88%) had a severe course. The concentration of IL-6 in children with a mild course of COVID-19 was 80.36 ng/ml; with a moderate course – 101 ng/ml; with a severe course – 151.90 ng/ml (р<0.001). The level of TNF-a in mild COVID-19 was 56.7 ng/ml; 97.73 ng/ml – in moderate disease severity, and 182.42 ng/ml – in severe cases (р<0.001).
Conclusions. The level of cytokines IL-6 and TNF-a in children with COVID-19 depends on the severity of the disease. Patients with severe COVID-19 have significantly higher levels of IL-6 and TNF-α compared to mild and moderate COVID-19. Correlative relationships between high levels of IL-6, TNF-α and C-reactive protein, ESR, and lymphocytes were found in children with COVID-19. No gender patterns were found in relation to cytokines (IL-6, TNF-α) and age-specific characteristics in relation to TNF-α indicators.
References
World Health Organization. Rolling updates on coronavirus disease (COVID-19). Retrieved from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019.
Wiersinga, W. J., Rhodes, A., Cheng, A. C., Peacock, S. J., & Prescott, H. C. (2020). Pathophysiology, transmission, diagnosis, and treatment of coronavirus disease 2019 (COVID-19): a review. Jama, 324(8), 782-793. DOI:10.1001/jama.2020.12839.
Yang, L., Liu, S., Liu, J., Zhang, Z., Wan, X., Huang, B., ... & Zhang, Y. (2020). COVID-19: immunopathogenesis and immunotherapeutics. Signal transduction and targeted therapy, 5(1), 128. DOI: 10.1038/s41392-020-00243-2.
Gu, Y., Wang, D., Chen, C., Lu, W., Liu, H., Lv, T., ... & Zhang, F. (2021). PaO2/FiO2 and IL-6 are risk factors of mortality for intensive care COVID-19 patients. Scientific reports, 11(1), 7334. DOI: 10.1038/s41598-021-86676-3.
Chen, G., Wu, D. I., Guo, W., Cao, Y., Huang, D., Wang, H., ... & Ning, Q. (2020). Clinical and immunological features of severe and moderate coronavirus disease 2019. The Journal of clinical investigation, 130(5), 2620-2629. DOI: 10.1172/JCI137244.
Del Valle, D. M., Kim-Schulze, S., Huang, H. H., Beckmann, N. D., Nirenberg, S., Wang, B., ... & Gnjatic, S. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature medicine, 26(10), 1636-1643. DOI: 10.1038/s41591-020-1051-9.
Niculet, E., Chioncel, V., Elisei, A. M., Miulescu, M., Buzia, O. D., Nwabudike, L. C., ... & Tatu, A. L. (2021). Multifactorial expression of IL 6 with update on COVID 19 and the therapeutic strategies of its blockade. Experimental and therapeutic medicine, 21(3), 1-1. DOI: 10.3892/etm.2021.9693.
Villar-Fincheira, P., Sanhueza-Olivares, F., Norambuena-Soto, I., Cancino-Arenas, N., Hernandez-Vargas, F., Troncoso, R., ... & Chiong, M. (2021). Role of interleukin-6 in vascular health and disease. Frontiers in molecular biosciences, 8, 641734. DOI: 10.3389/fmolb.2021.641734.
Majidpoor, J., & Mortezaee, K. (2022). Interleukin-6 in SARS-CoV-2 induced disease: Interactions and therapeutic applications. Biomedicine & Pharmacotherapy, 145, 112419. DOI: 10.1016/j.biopha.2021.112419.
Tagarro, A., Epalza, C., Santos, M., Sanz-Santaeufemia, F. J., Otheo, E., Moraleda, C., & Calvo, C. (2021). Screening and severity of coronavirus disease 2019 (COVID-19) in children in Madrid, Spain. JAMA pediatrics, 175(3), 316-317. DOI: 10.1001/jamapediatrics.2020.1346.
May, L. T., Viguet, H., Kenney, J. S., Ida, N., Allison, A. C., & Sehgal, P. B. (1992). High levels of “complexed” interleukin-6 in human blood. Journal of Biological Chemistry, 267(27), 19698-19704. Retrieved from: https://pubmed.ncbi.nlm.nih.gov/1527089/.
Dzis, I. Ye., Tomashevskaia, A. Ya., Dzis, Ye. I., & Danysh, O. Y. (2017). Prohnostychne znachennia markeriv systemnoho zapalennia dlia perebihu nehodzhkinskykh limfom i khronichnoi limfotsytarnoi leikemii [Prognostic value of markers of systemic inflammation for the course of non-Hodgkin's lymphoma and chronic lymphocytic leukemia]. Ukrainskyi medychnyi chasopys – Ukrainian medical journal , (3), 153-156. Retrieved from: http://nbuv.gov.ua/UJRN/UMCh_2017_3_35 [in Ukrainian].
Del Valle, D. M., Kim-Schulze, S., Huang, H. H., Beckmann, N. D., Nirenberg, S., Wang, B., ... & Gnjatic, S. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature medicine, 26(10), 1636-1643. DOI: 10.1038/s41591-020-1051-9.
Taghiloo, S., Soltanshahi, M., Aliyali, M., Abedi, S., Mehravaran, H., Ajami, A., & Asgarian-Omran, H. (2021). Cytokine profiling in Iranian patients with COVID-19; association with clinical severity. Iranian Journal of Immunology, 18(1), 54-64. DOI: 10.22034/IJI.2021.87630.1810.
Palacios, Y., & Chavez-Galan, L. (2022). Immunosuppressant therapies in COVID-19: is the TNF axis an alternative?. Pharmaceuticals, 15(5), 616. DOI: 10.3390/ph15050616.
Liu, B., Li, M., Zhou, Z., Guan, X., & Xiang, Y. (2020). Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?. Journal of autoimmunity, 111, 102452. DOI: 10.1016/j.jaut.2020.102452.
Vultaggio, A., Vivarelli, E., Virgili, G., Lucenteforte, E., Bartoloni, A., Nozzoli, C., ... & Matucci, A. (2020). Prompt predicting of early clinical deterioration of moderate-to-severe COVID-19 patients: usefulness of a combined score using IL-6 in a preliminary study. The Journal of Allergy and Clinical Immunology: In Practice, 8(8), 2575-2581. DOI: 10.1016/j.jaip.2020.06.013.
Remap-Cap Investigators. (2021). Interleukin-6 receptor antagonists in critically ill patients with Covid-19. New England Journal of Medicine, 384(16), 1491-1502. DOI: 10.1056/NEJMoa2100433.
Lasky, J. A., Fuloria, J., Morrison, M. E., Lanier, R., Naderer, O., Brundage, T., & Melemed, A. (2021). Design and rationale of a randomized, double-blind, placebo-controlled, phase 2/3 study evaluating dociparstat in acute lung injury associated with severe COVID-19. Advances in Therapy, 38, 782-791. DOI: 10.1007/s12325-020-01539-z.
Biran, N., Ip, A., Ahn, J., Go, R. C., Wang, S., Mathura, S., ... & Goldberg, S. L. (2020). Tocilizumab among patients with COVID-19 in the intensive care unit: a multicentre observational study. The Lancet Rheumatology, 2(10), e603-e612. DOI: 10.1016/S2665-9913(20)30277-0.
Del Valle, D. M., Kim-Schulze, S., Huang, H. H., Beckmann, N. D., Nirenberg, S., Wang, B., ... & Gnjatic, S. (2020). An inflammatory cytokine signature predicts COVID-19 severity and survival. Nature medicine, 26(10), 1636-1643. DOI: 10.1038/s41591-020-1051-9.
Mokhtari, T., Hassani, F., Ghaffari, N., Ebrahimi, B., Yarahmadi, A., & Hassanzadeh, G. (2020). COVID-19 and multiorgan failure: A narrative review on potential mechanisms. Journal of molecular histology, 51, 613-628. DOI: 10.1007/s10735-020-09915-3.].
Chen, X., Zhou, J., Chen, C., Hou, B., Ali, A., Li, F., ... & Men, D. (2021). Consecutive monitoring of interleukin-6 is needed for COVID-19 patients. Virologica Sinica, 36, 1093-1096. DOI: 10.1007/s12250-021-00425-4.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497-506. DOI: 10.1016/S0140-6736(20)30183-5.
Mauad, T., Duarte-Neto, A. N., da Silva, L. F. F., de Oliveira, E. P., de Brito, J. M., do Nascimento, E. C. T., ... & Dolhnikoff, M. (2021). Tracking the time course of pathological patterns of lung injury in severe COVID-19. Respiratory Research, 22(1), 1-11. DOI: 10.1186/s12931-021-01628-9.
Niculet, E., Chioncel, V., Elisei, A. M., Miulescu, M., Buzia, O. D., Nwabudike, L. C., ... & Tatu, A. L. (2021). Multifactorial expression of IL 6 with update on COVID 19 and the therapeutic strategies of its blockade. Experimental and therapeutic medicine, 21(3), 1-1. DOI: 10.3892/etm.2021.9693.
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., ... & Weinberger, T. (2020). Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. Journal of Allergy and Clinical Immunology, 146(1), 128-136. DOI: 10.1016/j.jaci.2020.05.008.
Huang, C., Wang, Y., Li, X., Ren, L., Zhao, J., Hu, Y., ... & Cao, B. (2020). Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. The Lancet, 395(10223), 497-506. DOI: 10.1016/S0140-6736(20)30183-5.
Mauad, T., Duarte-Neto, A. N., da Silva, L. F. F., de Oliveira, E. P., de Brito, J. M., do Nascimento, E. C. T., ... & Dolhnikoff, M. (2021). Tracking the time course of pathological patterns of lung injury in severe COVID-19. Respiratory Research, 22(1), 1-11. DOI: 10.1186/s12931-021-01628-9.
Niculet, E., Chioncel, V., Elisei, A. M., Miulescu, M., Buzia, O. D., Nwabudike, L. C., ... & Tatu, A. L. (2021). Multifactorial expression of IL 6 with update on COVID 19 and the therapeutic strategies of its blockade. Experimental and therapeutic medicine, 21(3), 1-1. DOI: 10.3892/etm.2021.9693.
Herold, T., Jurinovic, V., Arnreich, C., Lipworth, B. J., Hellmuth, J. C., von Bergwelt-Baildon, M., ... & Weinberger, T. (2020). Elevated levels of IL-6 and CRP predict the need for mechanical ventilation in COVID-19. Journal of Allergy and Clinical Immunology, 146(1), 128-136. DOI: 10.1016/j.jaci.2020.05.008.
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2024 Actual Problems of Pediatrics, Obstetrics and Gynecology
This work is licensed under a Creative Commons Attribution 4.0 International License.
Authors who publish in this journal agree to the following terms:
1. The authors reserve the right to authorship of the work and pass the journal right of first publication of this work is licensed under a Creative Commons Attribution License, which allows others to freely distribute the work published with reference to the authors of the original work and the first publication of this magazine.
2. Authors are entitled to enter into a separate agreement on additional non-exclusive distribution of work in the form in which it was published in the magazine (eg work place in the electronic repository institution or publish monographs in part), provided that the reference to the first publication of this magazine.
3. Policy magazine allows and encourages authors placement on the Internet (eg, in storage facilities or on personal websites) manuscript of how to submit the manuscript to the editor and during his editorial processing, since it contributes to productive scientific discussion and positive impact on the efficiency and dynamics of citing published work (see. The Effect of Open Access).
